hexoraletten n 5 mg+1,5 mg
jntl consumer health (france) s.a.s. - franta - combinatii (chlorhexidinum+benzocainum) - pastile - 5mg+1,5mg - medicamente pentru zona oro-faringiana antiseptice
imodium 2 mg
jntl consumer health (france) s.a.s. - franta - loperamidum - caps. - 2mg - antipropulsive (inhibitoare ale peristaltismului) antipropulsive
olygrip zi 500/60 mg si olygrip noapte 500/25 mg
jntl consumer health (france) sas - franta - combinatii - compr. + compr. film. - 500/60mg+500/25mg - alte analgezice si antipiretice anilide (inclusiv combinatii)
glucose intravenous infusion bp 100 mg/ml soluţie perfuzabilă
aculife healthcare private limited - glucoza - soluţie perfuzabilă - 100 mg/ml
avinew neo, vaccin
boehringer ingelheim animal health france scs, franța - virusul - comprimate efervescente
microlax
delpharm orlÉans - franta - combinatii - sol. rectala - laxative produse cu administrare intrarectala
tobi podhaler
viatris healthcare limited - tobramicina - cystic fibrosis; respiratory tract infections - antibacteriene pentru uz sistemic, - tobi podhaler este indicata pentru terapia de supresie infecţiei pulmonare cronice din cauza pseudomonas aeruginosa la adulţi şi copii cu vârsta între 6 ani şi mai în vârstă cu fibroza chistica. vezi secțiunile 4. 4 și 5. 1 privind datele din diferite grupe de vârstă. trebuie luate în considerare ghidurile oficiale referitoare la utilizarea adecvată a medicamentelor antibacteriene.
imodium 2 mg
janssen-cilag s.p.a - italia - loperamidum - compr. orodispersabile - 2mg - antipropulsive (inhibitoare ale peristaltismului) antipropulsive
calgel 3,3 mg/g+1 mg/g
famar orlÉans - franta - diverse - gel gingival - 3,3mg/g+1 mg/g - medicamente pentru cavitatea bucala alte medicamente pt. tratamentul local al cavitatii bucale
kalydeco
vertex pharmaceuticals (ireland) limited - ivacaftor - fibroză chistică - alte produse ale sistemului respirator - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 și 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 și 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.